CUREVAC N.V. O.N.
Commented by Stefan Feulner on May 27th, 2021 | 10:13 CEST
CureVac, NSJ Gold, Steinhoff - New opportunities every day
Following a performance of over 15% since the start of the year, the DAX seems to be running out of steam around the 15,500 mark. At least a short correction would be more than due here and only healthy to tackle the next barriers to the top. Gold was able to break through the USD 1,900 mark for the first time this year. It should now be a done deal that the correction that has been underway since August has come to an end. The general conditions of rising inflation fears and the further loose monetary policy of the central banks should soon help the precious yellow metal to new highs.
Read
Commented by Stefan Feulner on May 19th, 2021 | 08:39 CEST
CureVac, The Place Holdings, TUI - New start with great potential!
Finally! Due to the positive development of the vaccination program and the successful testing strategy, the incidence figures in Germany are gradually decreasing. Industries that suffered heavily from the pandemic, such as tourism and air travel, are breathing a sigh of relief. While Germans are still planning more domestic vacations during the Whitsun vacations, bookings abroad for the summer are rising disproportionately. Other countries are also increasingly focusing on domestic tourism, with considerable potential for the respective operators.
Read
Commented by André Will-Laudien on May 12th, 2021 | 09:36 CEST
Formycon, NanoRepro, CureVac, PsyBio Therapeutics - Beat Corona with these stocks!
The vaccination rate is moving steadily forward in Europe. The European Commission has ordered another 2 billion doses from BioNTech. After all the squabbling over AstraZeneca, that may not be a bad decision. But the successors in this market will soon be on the starting blocks. CureVac is close to the approval of its vaccine, and Formycon is making a push with a therapy. NanoRepro, a Company based in Marburg, Germany, wants to bring a highly valid antigen test to market that can give those already vaccinated clear information about the body's immune defenses. The pace in the health sector could not be higher at the moment.
Read
Commented by Stefan Feulner on May 10th, 2021 | 09:14 CEST
CureVac, Cardiol, MorphoSys - Huge sensation in the fight against Corona!
The biotechnology sector gained tremendous attention since the start of the Corona pandemic. With vaccine makers such as BioNTech or Moderna, investors have achieved returns beyond 1000% since the end of 2019. Currently, drug research against Sars-CoV-2 is in full swing. More effective and safe drugs along with vaccination and testing strategies are critical to managing the pandemic. For investors, this meant a second chance at the next tenbagger.
Read
Commented by Nico Popp on May 3rd, 2021 | 07:25 CEST
BioNTech, CureVac, Cardiol Therapeutics: In on the next blockbuster from the start
The two German companies BioNTech and CureVac, have been causing quite a stir since the outbreak of the pandemic. At first, the biotech newcomers were known only to hard-nosed investors who are used to seizing long-term opportunities and accepting initial uncertainty to do so. Even during the first months of the pandemic, it was far from clear whether BioNTech and CureVac would be successful. Only a few insiders had the right instinct early on thanks to the necessary background knowledge and are pleased with BioNTech's annual performance of 260%. But what characterizes the success of innovative biotech companies? And where are the next opportunities lurking? We outline some exciting investment stories.
Read
Commented by Stefan Feulner on April 28th, 2021 | 07:04 CEST
CureVac, PsyBio, Evotec - Revolution in the billion-dollar market!
The anxiety and limitations associated with the coronavirus pose major challenges for people suffering from depression. Officially, around 350 million people worldwide live with depression, but the number of unreported cases is significantly higher. At the moment, the number one cause of the disease is only combated with antidepressants; there are hardly any alternative treatment methods without severe side effects. A completely new field is currently emerging that could completely eclipse existing drugs, with incredible potential for the young companies.
Read
Commented by Stefan Feulner on April 20th, 2021 | 09:45 CEST
Varta, Sierra Growth, CureVac - Clear signals!
Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.
Read
Commented by Nico Popp on April 20th, 2021 | 06:50 CEST
CureVac, BioNTech, PsyBio: Yesterday's game changers - and tomorrow's?
Vaccines against the coronavirus are changing everything. People who sat anxiously at home just a few weeks ago now dare to socialize again after their injection. Even if contact restrictions still apply - the feeling of being alive is different after the vaccination. German vaccine manufacturers, in particular, have used innovative mRNA technology to create vaccines that are largely scandal-free - and offer good protection. In the slipstream, new, innovative companies are already preparing to bring the next game changers to market. For investors, this can be a rewarding environment.
Read
Commented by Stefan Feulner on April 15th, 2021 | 07:15 CEST
Alibaba, The Place Holdings, CureVac - Great opportunities lie here!
The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?
Read
Commented by Stefan Feulner on March 24th, 2021 | 09:06 CET
CureVac, Scottie Resources, Newmont - Is the monetary system at its end?
There is a dangerous mix brewing in the international financial markets. With the passage of the new USD 1.9 trillion US stimulus package, whose money will be used primarily to boost consumption, inflation expectations rise. The Fed expects inflation to average 2.4% in 2021. Nevertheless, the Fed intends to continue its path of loose monetary policy, which was accelerated during the Corona Crisis, until at least 2023. In doing so, Fed Chairman Powell violates the basic principle of central banks to take preventive action against inflation. There is a threat of monetary devaluation of historic proportions.
Read